Concomitant Cholecystectomy During Bariatric Surgery: 79% of Patients Who Skip It Develop Symptomatic Gallstones

Heikal MA, Negm AMR, Elghabdan HM, Aziz MA — J Obes. 2026;2026:6054585

In this prospective randomized controlled pilot study from Egypt, 58 morbidly obese patients with ultrasound-confirmed gallstones were assigned to laparoscopic sleeve gastrectomy with concomitant cholecystectomy (Group I, n=30) versus sleeve gastrectomy alone with cholecystectomy deferred (Group II, n=28). Concomitant LC added approximately 24 minutes of operative time and produced higher postoperative pain scores, but generated no significant differences in bleeding, bile leakage, postoperative complications, or hospital length of stay. During follow-up, 79.3% of the deferred-LC group developed symptomatic gallstones requiring interval cholecystectomy, providing prospective randomized support for a routine concomitant approach in morbidly obese patients presenting with pre-existing gallstone disease.

YouTube Bariatric Surgery Videos Score “Poor” on Quality — Weight-Loss Medication Videos Score Higher But Are More Negative in Tone

Botvinov J, Henrich M, Deng Q, Jawed A, Merchant AM — Surg Endosc. Published online April 13, 2026

Researchers from Hackensack Meridian School of Medicine analyzed 129 weight-loss surgery (WLS) and 111 weight-loss medication (WLM) YouTube videos using the 16-item DISCERN instrument to compare informational quality and perceived tone. WLM videos scored significantly higher on DISCERN (“fair,” mean 46.69) than WLS videos (“poor,” mean 40.32; p=0.0366), largely attributable to their predominantly informational and commercially uploaded nature; WLS content originated more frequently from academic centers (50%) and included more patient experience material (49%). Tone differed significantly between categories (p<0.01): 60% of WLS videos were positive versus 44% of WLM videos, while WLM carried notably more negative content (14% vs. 4%) — a disparity with implications for patient attitudes toward surgical referral.

MSA (LINX) Erosion After Sleeve Gastrectomy: 3.8% Rate — Up to 30× Higher Than Non-Bariatric Populations

Noel P, Jacobs M — Surg Obes Relat Dis. 2026;22:525–535

This systematic review and meta-analysis pooled 14 studies encompassing 287 patients with a median follow-up of 24 months to quantify device erosion rates following magnetic sphincter augmentation (MSA/LINX) after laparoscopic sleeve gastrectomy for post-LSG GERD. The overall erosion rate was 3.8% (11/287; 95% CI 1.9%–6.7%), significantly higher than the 0.1%–0.3% rate in nonbariatric populations (P<0.001), with independent risk factors including absent hiatal hernia repair (OR 4.1), device undersizing (OR 3.8), BMI >30 kg/m² at MSA placement (OR 3.2), and persistent sleeve dilatation (OR 2.7). Median time to erosion was 18 months; all required device explantation (primarily laparoscopic); 90.9% achieved symptom resolution — and critically, both prospective studies with rigorous patient selection protocols reported 0% erosion, underscoring that careful case selection may largely govern risk.

Preoperative pH Monitoring Predicts Post-Sleeve GERD: Normal 24-h pHmetry Associated with 3× Lower Esophagitis Rate

Mosquera GCL, Lopes KG, Gonçalves MM, Leal PRF, Kraemer-Aguiar LG — Obes Surg. 2026;36:1004–1014

In this retrospective study of 120 sleeve gastrectomy patients divided into three groups — no preoperative pH monitoring (NMG, n=40), normal pH monitoring (NG, n=40), and abnormal pH monitoring (AG, n=40) — preoperative 24-hour pHmetry significantly stratified postoperative GERD outcomes at 12 months. Grade B esophagitis developed in 7.5% of the NG group versus 25% in both the NMG and AG groups; positive Gerd-Q scores were lowest in the AG group (12.5%) compared to 47.5% in both NMG and NG groups, with the AG cohort more likely triaged to fundoplication rather than sleeve. The authors conclude that normal preoperative 24-h pH monitoring predicts a significantly lower postoperative GERD burden after LSG, while absent monitoring carries equivalent reflux risk to abnormal baseline pH.

MBS Outperforms GLP-1 Receptor Agonists at 2 Years — But Tirzepatide Narrows the Gap: Network Meta-Analysis

Sabatella L, Ortega PM, Valentí Azcárate V et al. — Obesity. 2026;34:770–781

This network meta-analysis included 30 RCTs (20,015 patients) comparing metabolic/bariatric surgery or GLP-1 receptor agonists against lifestyle intervention using indirect comparison methods, as no direct head-to-head RCTs currently exist. At less than 104 weeks, MBS achieved significantly greater reductions in %TWL (ETD −10.3%; p=0.001), BMI (−4.5 kg/m²; p<0.001), body weight (−11.7 kg; p<0.001), waist circumference (−12.6 cm; p<0.001), and HbA1c (−0.5%; p=0.033) versus GLP-1 agents; at ≥104 weeks, %TWL (−9.1%; p=0.022) and absolute weight loss (−14.6 kg; p=0.049) advantages persisted. However, when restricted to tirzepatide comparisons, differences versus MBS were no longer statistically significant — positioning tirzepatide as the pharmacotherapy agent that most substantially narrows the surgical efficacy gap.

AI Scans 400,000 Reddit Posts to Surface Underreported GLP-1 Side Effects — Including Menstrual Irregularities

Sehgal NKR et al. — Nat Health. Published online April 2026

Penn researchers applied an NLP/AI pipeline to 410,198 Reddit posts from May 2019–June 2025, identifying 67,008 users self-reporting semaglutide or tirzepatide use, 43.5% of whom described at least one side effect. The predominant symptoms aligned with known trial data — nausea (36.9%), fatigue (16.7%), vomiting (16.3%), constipation (15.3%), diarrhea (12.6%) — but AI analysis also flagged potential underreported effects including menstrual irregularities (~4% of users) and temperature dysregulation (chills, hot flushes) not systematically captured in RCTs. Published in Nature Health, this study represents the largest real-world GLP-1 pharmacovigilance dataset assembled to date, and suggests the predominantly female bariatric population warrants targeted counseling about reproductive and hormonal effects both upstream of and after surgical referral.

YouTube Bariatric Surgery Videos Score “Poor” on Quality — GLP-1 Medication Videos Score Higher But Carry More Negative Tone

Botvinov J, Henrich M, Deng Q, Jawed A, Merchant AM — Surg Endosc. Published online April 13, 2026

Researchers from Hackensack Meridian School of Medicine analyzed 129 weight-loss surgery (WLS) and 111 weight-loss medication (WLM) YouTube videos using the 16-item DISCERN instrument to compare informational quality and perceived tone. WLM videos scored significantly higher on DISCERN (“fair,” mean 46.69) than WLS videos (“poor,” mean 40.32; p=0.0366), largely attributable to their predominantly informational and commercially uploaded nature; WLS content originated more frequently from academic centers (50%) and included more patient experience material (49%). Tone differed significantly between categories (p<0.01): 60% of WLS videos were positive versus 44% of WLM videos, while WLM carried notably more negative content (14% vs. 4%) — a disparity with direct implications for patient attitudes toward surgical referral in the era of expanding GLP-1 access.

ChatGPT for Obesity Management: Evidence Is Promising But Limitations Are Real — Lancet Digital Health Review

Metwalli M, Bavaresu B, Stanford FC — Lancet Digit Health. 2026

This systematic review searched PubMed and Web of Science for studies addressing ChatGPT applications in weight management published through October 2025, ultimately including 37 studies across six functional domains: lifestyle behavior change, clinical empowerment, surgical guidance, patient education, user engagement, and medical education. In bariatric surgery contexts specifically, ChatGPT alignment with ASMBS clinical guidelines ranged from 60% to 91% across studies, with stronger performance for structured preoperative guidance queries and weaker performance on complex, nuanced clinical scenarios requiring individualized judgment. The review identifies six challenges critical to clinical deployment — accuracy and reliability, algorithmic bias, cultural sensitivity, transparency, accountability, and emotional dependency — and concludes that ChatGPT holds real promise as a supplementary obesity management tool but requires prospective validation frameworks before being integrated into clinical-grade workflows.

Fellowship After General Surgery: Only Cardiothoracic, Plastic, and Pediatric Consistently Yield Positive Financial Returns

Donaghue JF, Denson DJ, Carroll MC, Smith JE, Rosenkranz KM — J Surg Educ. 2025;82:103734

Using AAMC academic and MGMA private-practice salary data modeled over a 35-year career, Donaghue et al. quantified the net present value (NPV) and breakeven timeline for 10 surgical subspecialties compared with direct entry into general surgery practice following 5-year or 7-year (with research years) residency. Cardiothoracic, Plastic, and Pediatric surgery generated positive NPVs in both academic and private-practice settings even when accounting for 7 years of residency including research time; Breast, Colorectal, Surgical Oncology, Transplant, and Trauma/Critical Care produced negative NPVs across both environments, while Vascular broke even only in private practice without the research-year pathway. Published in the Journal of Surgical Education, the analysis provides a transparent financial framework directly relevant to MBS trainees — for whom a 1-year bariatric fellowship carries a comparatively modest opportunity cost relative to the multi-year subspecialty paths examined, making the ROI calculation more favorable across most practice types.

FDA Flags Safety Signals for Newly Approved Foundayo™ — CV Events, Liver Injury, and Retained Gastric Contents Prompt Postmarketing Trial Requirement

BioSpace — April 2026

Within weeks of Foundayo™’s (orforglipron) April 1, 2026 approval, the FDA identified three postmarketing safety signals warranting further investigation: retained gastric contents, unexpected major adverse cardiovascular events (MACE), and drug-induced liver injury (DILI). The agency determined that only a dedicated clinical trial — not a nonclinical or observational study — would adequately assess the cardiovascular and hepatic risks, directing Lilly to use the ongoing Phase 3 ACHIEVE-4 trial (type 2 diabetes/obesity/elevated CV risk population, completion expected July 2026) to generate DILI outcome data; additional postmarketing studies covering pregnancy outcomes and thyroid cancer potential were also requested. Lilly did not respond to requests for comment at the time of publication; BMO Capital Markets characterized the FDA’s requests as “manageable” and not expected to disrupt Foundayo’s competitive positioning against Novo Nordisk’s oral semaglutide.

OpenAI Partners With Novo Nordisk to Accelerate Drug Development — AI Licensing Model Would Share Drug Sales Revenue

Boyle B — The Daily Upside. April 15, 2026

OpenAI announced a strategic partnership with Novo Nordisk on April 15, 2026, to integrate artificial intelligence across the pharmaceutical giant’s research, manufacturing, and commercial operations — the latest in OpenAI’s pivot toward enterprise revenue, which now represents 40% of total company revenue with expectations of reaching parity with consumer revenue by year-end. The collaboration advances a model floated by OpenAI CFO Sarah Friar in which the company would receive a portion of sales from AI-developed drugs — a precedent with significant implications if applied to Novo Nordisk’s obesity and metabolic disease portfolio, including semaglutide and CagriSema. For the MBS field, the partnership signals that AI-accelerated discovery timelines at the world’s dominant GLP-1 manufacturer may further compress the window between current surgical indications and emerging pharmacological alternatives.

Utah Approves First AI Prescription Renewal Agreement — Doctronic Pilot Automates Refills Under Physician Oversight

Utah Office of Artificial Intelligence Policy — Regulatory Mitigation Agreement, 2026

Utah’s Office of Artificial Intelligence Policy approved a first-of-kind AI Regulatory Mitigation Agreement permitting Doctronic, a health technology company, to use AI to process 30-, 60-, and 90-day prescription renewals for previously prescribed non-controlled medications under mandatory licensed physician authorization in a Phase 1 pilot. The system automates guideline-based renewal decisions only — it cannot issue new prescriptions, modify treatment plans, or handle controlled substances — and employs identity and prescription verification with a three-tier risk-stratification framework (“no risk,” “minor risk,” “minor-to-moderate risk”). With no serious safety incidents reported to date, the Utah pilot represents an early regulatory template for AI-assisted medication management with direct implications for post-bariatric prescription workflows, including maintenance pharmacotherapy refills, where administrative burden on surgical programs continues to grow.

LLY — Eli Lilly

1-week change: +1.4%

Apr 7, 2026 – Apr 11, 2026

NVO — Novo Nordisk

1-week change: +2.3%

Apr 7, 2026 – Apr 11, 2026

ISRG — Intuitive Surgical

1-week change: +7.2%

Apr 7, 2026 – Apr 11, 2026

JNJ — Johnson & Johnson

1-week change: +2.7%

Apr 7, 2026 – Apr 11, 2026

TFX — Teleflex

1-week change: +6.4%

Apr 7, 2026 – Apr 11, 2026